Inprosub (Progesterone)

Progesterone in Inprosub acts on the hormonal pathways that regulate the menstrual cycle and early pregnancy.

• Luteal phase support in assisted reproductive technology: maintains the uterine lining to improve implantation success.
• Prevention of preterm birth in women with a history of recurrent miscarriage: helps sustain pregnancy until term.
• Hormone replacement therapy in post‑menopausal women: alleviates symptoms associated with low progesterone levels.

• Progesterone binds to intracellular progesterone receptors, forming a hormone‑receptor complex that translocates to the nucleus. This complex modulates gene transcription, leading to changes in endometrial maturation, suppression of uterine contractility, and preparation of the reproductive tract for implantation and pregnancy maintenance.

Progesterone therapy can be associated with a range of adverse reactions.

Common Side Effects

• Injection site pain or irritation: mild discomfort at the administration site.
• Headache: transient, often resolves without intervention.
• Nausea or mild gastrointestinal upset.
• Breast tenderness or swelling.
• Mood changes: irritability or mild depression.
• Fluid retention: mild edema.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or anaphylaxis.
• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe hypertension: sudden increase in blood pressure.
• Liver dysfunction: abnormal liver enzymes.
• Hyperglycemia: elevated blood glucose levels.
• Severe mood disturbances: suicidal ideation.

When prescribing Inprosub, clinicians should consider several safety measures.

• Assess patient history: evaluate for clotting disorders, hypertension, or liver disease.
• Monitor hormone levels: adjust therapy based on serum progesterone concentrations.
• Review concomitant medications: avoid drugs that increase thrombosis risk.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Patient counseling: inform about possible injection site reactions and systemic effects.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Progesterone may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• CYP3A4 inducers (e.g., rifampin): reduced progesterone plasma levels.
• Hormonal contraceptives: potential additive hormonal effects.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: possible hyperglycemia.
• Antihypertensives: may affect blood pressure control.
• Certain antibiotics (e.g., macrolides): modest impact on metabolism.